Literature DB >> 11520137

Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?

S M Eisenkop1, N M Spirtos.   

Abstract

OBJECTIVE: The aim of this study was to determine if the necessity of using specific procedures to attain complete cytoreduction in ovarian cancer correlates with innate biologic aggressiveness and independently influences survival.
METHODS: Between 1990 and 2000, 213 patients with Stage IIIC epithelial ovarian cancer underwent complete cytoreduction before initiation of systemic platinum-based combination chemotherapy. Survival was stratified and analyzed (log rank and Cox regression) on the basis of whether extrapelvic bowel resection, diaphragm stripping, full-thickness diaphragm resection, modified posterior pelvic exenteration, peritoneal implant ablation and/or aspiration, and excision of grossly involved retroperitoneal lymph nodes were necessary to attain a visibly disease-free cytoreductive outcome.
RESULTS: The median and estimated 5-year survival for the cohort were 75.8 months and 54%, respectively. Survival was influenced (log rank) by the requirement of diaphragm stripping (required, median 42 months vs not required, median 79 months; P = 0.03) and the extent of mesenteric and serosal implants that required removal (none, median not reached, vs 1-50 implants, median not reached, vs >50 implants, median 40 months; P = 0.002). Survival was independently influenced (Cox regression) only by the extent of peritoneal metastatic implants that required removal (P = 0.01). The other investigated procedures and type of chemotherapy used did not influence survival.
CONCLUSIONS: The need to remove a large number of peritoneal implants correlates with biological aggressiveness and diminished survival, but not significantly enough to preclude long-term survival or justify abbreviation of the operative effort. The need to use the other investigated procedures had minimal or no observed influence on survival. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520137     DOI: 10.1006/gyno.2001.6313

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.

Authors:  Neil S Horowitz; Austin Miller; Bunja Rungruang; Scott D Richard; Noah Rodriguez; Michael A Bookman; Chad A Hamilton; Thomas C Krivak; G Larry Maxwell
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

Authors:  Oliver Zivanovic; Camelia S Sima; Alexia Iasonos; William J Hoskins; Pavani R Pingle; Mario M M Leitao; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2010-03       Impact factor: 5.482

3.  Clinical Significance of Mesenteric Lymph Node Involvement in the Pattern of Liver Metastasis in Patients with Ovarian Cancer.

Authors:  Kana Tanaka; Yoshifumi Shimada; Koji Nishino; Kosuke Yoshihara; Masato Nakano; Hitoshi Kameyama; Takayuki Enomoto; Toshifumi Wakai
Journal:  Ann Surg Oncol       Date:  2021-04-05       Impact factor: 5.344

4.  Extraperitoneal Approach During Peritonectomy in the Right Upper Quadrant for Peritoneal Metastases from Ovarian Malignancies.

Authors:  Miklos Acs; Hubert Leebmann; Sebastian Häusler; Philipp Harter; Pompiliu Piso
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 5.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Shaun Hiu; Andrew Bryant; Ketankumar Gajjar; Patience T Kunonga; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-08-30

6.  Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.

Authors:  Sean C Dowdy; Ralitsa T Loewen; Giovanni Aletti; Simone S Feitoza; William Cliby
Journal:  Gynecol Oncol       Date:  2008-04-01       Impact factor: 5.482

7.  Subtotal Colectomy as Part of Debulking Surgery for Advanced-stage Ovarian Cancer.

Authors:  Nicolae Bacalbasa; Camelia Diaconu; Laura Iliescu; Simona Dima; Ovidiu Gabriel Bratu; Dragos Cretoiu; Adrian Neacsu; Alexandru Filipescu; Cornel Savu; Irina Balescu
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

8.  Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer.

Authors:  Nicolae Bacalbasa; Irina Balescu; Cristian Balalau; Olivia Ionescu; Claudia Stoica
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

Review 9.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Christine Ang; Karen K L Chan; Andrew Bryant; Raj Naik; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

10.  When should surgical cytoreduction in advanced ovarian cancer take place?

Authors:  Igor E Martinek; Sean Kehoe
Journal:  J Oncol       Date:  2009-10-25       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.